Three clinical trials centers now open for enrollment; two additional ones initiating
LOS ALTOS, Calif., January 9, 2020 -- Retrotope announced today that it has dosed its first
patient in a Phase 2/3 clinical trial of RT001 in Friedreich’s ataxia, the most common of the
inherited ataxias. RT001, a stabilized fatty acid drug, has been shown to reduce lipid
peroxidation leading to cell death in patients across a wide swath of degenerative diseases,
including FA. More information and a list of participating clinical sites for the current trial in FA
can be obtained at ClinicalTrials.gov http://bit.ly/2T2FWA5. With this trial, the company expands its pipeline of indications for RT001 which is currently being studied in a pivotal trial in another fatal, neurodegenerative disease, Infantile Neuroaxonal Dystrophy (INAD), which is fully enrolled.
View the entire Press Release HERE
Please wait while your page loads ...
Archived in
2020 (49)